309 related articles for article (PubMed ID: 18470505)
1. Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.
Li JX; McMahon LR; Gerak LR; Becker GL; France CP
Psychopharmacology (Berl); 2008 Aug; 199(2):199-208. PubMed ID: 18470505
[TBL] [Abstract][Full Text] [Related]
2. Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration.
Maguire DR; Yang W; France CP
J Pharmacol Exp Ther; 2013 Jun; 345(3):354-62. PubMed ID: 23536317
[TBL] [Abstract][Full Text] [Related]
3. Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl.
Maguire DR; France CP
Eur J Pharmacol; 2016 Aug; 784():199-206. PubMed ID: 27184925
[TBL] [Abstract][Full Text] [Related]
4. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
5. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.
Solinas M; Goldberg SR
Psychopharmacology (Berl); 2005 Jun; 179(4):804-12. PubMed ID: 15619107
[TBL] [Abstract][Full Text] [Related]
6. Combined Treatment with Morphine and Δ9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal.
Gerak LR; France CP
J Pharmacol Exp Ther; 2016 May; 357(2):357-66. PubMed ID: 26937020
[TBL] [Abstract][Full Text] [Related]
7. Some effects of dopamine transporter and receptor ligands on discriminative stimulus, physiologic, and directly observable indices of opioid withdrawal in rhesus monkeys.
McMahon LR; Li JX; Carroll FI; France CP
Psychopharmacology (Berl); 2009 Apr; 203(2):411-20. PubMed ID: 18636243
[TBL] [Abstract][Full Text] [Related]
8. Antagonism of the antinociceptive and discriminative stimulus effects of heroin and morphine by 3-methoxynaltrexone and naltrexone in rhesus monkeys.
Bowen CA; Fischer BD; Mello NK; Negus SS
J Pharmacol Exp Ther; 2002 Jul; 302(1):264-73. PubMed ID: 12065726
[TBL] [Abstract][Full Text] [Related]
9. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
Stewart JL; McMahon LR
J Pharmacol Exp Ther; 2010 Jul; 334(1):347-56. PubMed ID: 20375197
[TBL] [Abstract][Full Text] [Related]
10. JWH-018 and JWH-073: Δ⁹-tetrahydrocannabinol-like discriminative stimulus effects in monkeys.
Ginsburg BC; Schulze DR; Hruba L; McMahon LR
J Pharmacol Exp Ther; 2012 Jan; 340(1):37-45. PubMed ID: 21965552
[TBL] [Abstract][Full Text] [Related]
11. Functional consequences of short-term exposure to opioids versus cannabinoids in nonhuman primates.
Ding H; Kiguchi N; Mabry KM; Kishioka S; Ko MC
Neuropharmacology; 2023 Feb; 223():109328. PubMed ID: 36356937
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the Discriminative Stimulus Effects of a NOP Receptor Agonist Ro 64-6198 in Rhesus Monkeys.
Saccone PA; Zelenock KA; Lindsey AM; Sulima A; Rice KC; Prinssen EP; Wichmann J; Woods JH
J Pharmacol Exp Ther; 2016 Apr; 357(1):17-23. PubMed ID: 26801398
[TBL] [Abstract][Full Text] [Related]
13. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
[TBL] [Abstract][Full Text] [Related]
14. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors.
Smith PA; Selley DE; Sim-Selley LJ; Welch SP
Eur J Pharmacol; 2007 Oct; 571(2-3):129-37. PubMed ID: 17603035
[TBL] [Abstract][Full Text] [Related]
15. THC-methadone and THC-naltrexone interactions on discrimination, antinociception, and locomotion in rats.
Wakley AA; Craft RM
Behav Pharmacol; 2011 Sep; 22(5-6):489-97. PubMed ID: 21716095
[TBL] [Abstract][Full Text] [Related]
16. Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy µ opioid receptor agonist and a δ opioid receptor antagonist.
Mada S; Gerak LR; Soyer A; Maguire DR; Hu Z; Minervini V; Cunningham CW; France CP
Psychopharmacology (Berl); 2020 Dec; 237(12):3591-3602. PubMed ID: 32820390
[TBL] [Abstract][Full Text] [Related]
17. Impact of efficacy at the μ-opioid receptor on antinociceptive effects of combinations of μ-opioid receptor agonists and cannabinoid receptor agonists.
Maguire DR; France CP
J Pharmacol Exp Ther; 2014 Nov; 351(2):383-9. PubMed ID: 25194020
[TBL] [Abstract][Full Text] [Related]
18. Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys.
Schulze DR; Carroll FI; McMahon LR
Psychopharmacology (Berl); 2012 Aug; 222(3):425-38. PubMed ID: 22374253
[TBL] [Abstract][Full Text] [Related]
19. Apparent affinity of opioid antagonists in morphine-treated rhesus monkeys discriminating between saline and naltrexone.
France CP; de Costa BR; Jacobson AE; Rice KC; Woods JH
J Pharmacol Exp Ther; 1990 Feb; 252(2):600-4. PubMed ID: 2156055
[TBL] [Abstract][Full Text] [Related]
20. Comparison of naltrexone, 6alpha-naltrexol, and 6beta-naltrexol in morphine-dependent and in nondependent rhesus monkeys.
Li JX; McMahon LR; France CP
Psychopharmacology (Berl); 2008 Jan; 195(4):479-86. PubMed ID: 17874317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
